Abstract
Introduction
. Particularly relevant to this review, several pieces of evidence indicate prognostic significance of VEGF in high-grade astrogliomas [6] [7] [8] [20] [21] [22] [23] [24] . These cells express a number of NSC markers including CD133, a cell surface protein which is extensively exploited for enrichment of stem-like cells using fluorescence activated cell sorting (FACS) and/or magnetic bead separation, thereby providing cells to be examined in diverse applications [25] [26] . The human CD133 antigen, also known as AC133, was originally identified as a marker of haematopoietic stem cells, however its function has remained unclear [27] . A characteristic feature of the CD133 protein is its rapid down-regulation during cell differentiation [28] [29] [20-22, 24, 32-33] . As few as 100 CD133-positive human cells were sufficient to form brain tumours as xenografts in NOD-SCID mice [22] . Importantly, the CD133-positive BTCSCs also exhibit high resistance to current chemotherapy and radiotherapy, in contrast to their CD133-negative counterparts [33] [34] 
Angiogenesis in astrogliomas
Angiogenesis is a highly regulated process essential not only in early embryogenesis but also during tissue growth and repair, female reproductive cycle and diverse pathologies, such as inflammation or tumour development and progression [35] [36] [6, [38] [39] [40] [41] [42] [43] . Recent work [44] identified the BTCSCs to be a key source of angiogenic factors in brain cancer, suggesting that anti-angiogenic therapy targeting these stem-like tumour cell sub-populations might improve the therapy outcome. Exuberant angiogenesis is a key event in astroglioma progression [45] [46] [47] . Understanding angiogenesis and its relation to tumour growth and resistance to therapy is of considerable interest, particularly because diffusely infiltrating astrogliomas are mostly refractory to current surgical and adjuvant treatments [48] .
. Localized breakdown of extracellular matrix (ECM) precedes proliferation, migration and tissue infiltration of endothelial cells. In time these cells re-model back into capillary structures, and a new ECM is deposited [37]. Highly malignant astrogliomas exhibit striking angiogenesis and markedly increased expression of VEGF (Fig. 1). VEGF expression strongly correlates with tumour aggressiveness, metastatic potential, a short time to relapse and, consequently, it commonly indicates poor prognosis in patients with cancer
Neovascularization in brain tumours correlates markedly with their enhanced aggressiveness, degree of malignancy and poor clinical prognosis and inversely with the post-operative survival time of patients [49] [50] [51] . Newly formed tumour blood vessels possess an ineffective blood-brain barrier that contributes to the pathogenesis of tumour-associated oedema [52] . The [62] [63] [64] . Secretion of VEGF, in turn, causes endothelial cell proliferation and angiogenesis followed by microvascular hyperplasia and formation of glomeruloid bodies in GBM and other tumours [65] [66] .
Overexpression of VEGF by tumour cells frequently occurs not only in response to hypoxia [62, 67] , but also upon loss of function of certain tumour suppressor genes [68] [69] and oncogene activation [70] . Under hypoxic conditions, transcriptional regulation of VEGF is dominated by HIF-1 that, together with its target genes, plays a key role in astroglioma-induced angiogenesis [71] [72] (Fig. 2) , an autocrine role of the VEGF in GBM might significantly contribute to tumour growth and invasivity [93] [94] [95] . On the other hand, in contrast to VEGFs well-established paracrine effects on endothelial cells, less is known about such potential autocrine role of VEGF in glioblastoma. While some authors [96] reported that exogenous VEGF not only stimulates endothelial cells, but also directly enhances astroglioma cell motility, invasion and proliferation (Fig. 3A) , others published virtually opposite effects [97] and this issue remains controversial. 
Despite our effort to understand the stem cell niche is in its infancy, particularly with regard to the BTCSC niche and its potential aberrant features, recent studies in this area are encouraging and support a crucial role of a perivascular niche for brain tumour stem-like cells [92, 98]. The emerging significance of this concept for development of new

Fig. 2 Schematic representation of membrane VEGF receptors expressed by astroglial tumour cells. Known receptor types are indicated and identified ligands/ligand isoforms are listed directly in the figure above. Cell membrane (GC membrane) receptors of the VEGF tyrosine kinase receptor family consist of seven Ig-like domains, transmembrane region and an intracellular tyrosine kinase binding domain interrupted by a kinase-insert sequence. The aberrant sFlt-1 receptor form lacking one Ig-like domain as a result of VEGFR1 truncation is also shown. The neuropilin receptor acts as a co-receptor for VEGFR2, enhancing binding and biological activity of VEGF165. Ligand binding through electrostatic interactions with specific sequences of sulphation within the HS chains leads to receptor dimerization and tyrosine domain phosphorylation, thereby activating the corresponding signalling pathway.
Fig. 3 Autocrine and paracrine effects of VEGF signalling in astrogliomas. (A) VEGF secreted by tumour endothelial cells (orange) induces angiogenesis in an autocrine manner, while VEGF secreted by astroglial tumour cells (pink) stimulates tumour angiogenesis in a paracrine manner. As reports on other biological effects of the autocrine VEGF function in astroglial tumour cells are currently contradictory, this aspect remains to be clarified by further studies. (B) Hypothetical distinct effects of VEGF on the CD133-positive (VEGF secreting and radioresistant [34,44]) versus CD133-negative (radiosensitive) astroglial cell population. IR-induced VEGF secretion by the CD133-positive astroglial cells (cancer stem-like cells) could enhance tumour angiogenesis and protection of endothelial cells against apoptosis. Furthermore, IR-induced VEGF could modulate proliferation of the CD133-positive cells, thereby regulating their sensitivity to IR. IR-induced VEGF, massively secreted by the CD133-positive astroglial cell sub-population, might also help to protect these cells from apoptosis and increase their migration in an autocrine manner. astroglioma treatment strategies is discussed in the ultimate section of this article.
Resistance to DNA-damaging therapy in astrogliomas
VEGF and DNA damage response: implications for astroglioma therapy
In response to IR, VEGF secretion by GBM cell lines was highly increased in a radiation dose-dependent manner [94, 111] . Among all the cell lines tested, the U87MG is highly radioresistant and expresses the highest IR-induced VEGF levels [111] , a correlation that inspired a hypothesis about a potential involvement of IR-enhanced VEGF secretion in radioresistance. Based on observations of decreased GBM cell proliferation in response to exogenous VEGF [97] , it was proposed that expression of VEGF would at the same time induce growth of new blood vessels ensuring a better supply of oxygen and nutrients and reduce GBM cell proliferation resulting in decreased sensitivity to IR. Since proliferating cells are more sensitive to irradiation than quiescent cells [112] and since VEGF protects tumour blood vessels from irradiation-mediated toxicity [94] , this suggests a possible mechanism through which GBM cells can escape the consequences of radiation treatment.
After irradiation, the VEGF gene promoter becomes stimulated via multiple mitogen-activated protein kinase (MAPK) dependent pathways in both cultured normal human astrocytes and GBM cell lines [113] . Since HIF-1 was not overexpressed under such conditions, hypoxia doesn't seem to be involved in this mechanism [113] . Given the radioresistance of BTCSCs discussed in the previous section [34] (Fig. 3B) (Fig. 4) [126] [127] [128] [129] . Better mechanistic understanding of these biological processes appears to be more plausible based on the recent advances in the field, and such research will hopefully help to improve the presently dismal prognosis of astroglioma patients. 
